Cointime

Abivax

company

About

Abivax is a pioneering biotech company.

  • 11 - 50

Highlights

Total Funding Amount
€35M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
€15M
Industries
Biotechnology
Founded date
Jan 1, 2013
Number Of Employee
11 - 50
Operating Status
Active

Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€35M
Abivax has raised a total of €35M in funding over 2 rounds. Their latest funding was raised on Oct 13, 2020 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 13, 2020 Post-IPO Debt €15M 1 Kreos Capital — Detail
Jul 25, 2018 Post-IPO Debt €20M 1 Kreos Capital — Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Abivax is funded by 1 investors. Kreos Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Kreos Capital Yes Post-IPO Debt
Cointime
เนื้อหา
บริษัท